Sign in or create an account to add this stock to your watchlist.
About Biocept (NASDAQ:BIOC)
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200
Debt
Debt-to-Equity Ratio0.13
Current Ratio2.41
Quick Ratio2.31
Price-To-Earnings
Trailing P/E Ratio-0.23
Forward P/E Ratio-0.65
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.07 million
Price / Sales2.46
Cash FlowN/A
Price / CashN/A
Book Value$0.12 per share
Price / Book1.52
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-21,610,000.00
Net Margins-561.47%
Return on Equity-445.14%
Return on Assets-196.63%
Miscellaneous
Employees95
Outstanding Shares68,210,000
Biocept (NASDAQ:BIOC) Frequently Asked Questions
What is Biocept's stock symbol?
Biocept trades on the NASDAQ under the ticker symbol "BIOC."
How were Biocept's earnings last quarter?
Biocept (NASDAQ:BIOC) issued its quarterly earnings data on Tuesday, May, 15th. The medical research company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.03. The medical research company had revenue of $0.81 million for the quarter, compared to the consensus estimate of $1.21 million. Biocept had a negative net margin of 561.47% and a negative return on equity of 445.14%. View Biocept's Earnings History.
When is Biocept's next earnings date?
What price target have analysts set for BIOC?
2 analysts have issued 12-month price objectives for Biocept's stock. Their forecasts range from $1.00 to $1.50. On average, they expect Biocept's stock price to reach $1.25 in the next twelve months. View Analyst Ratings for Biocept.
Who are some of Biocept's key competitors?
Who are Biocept's key executives?
Biocept's management team includes the folowing people:
- Mr. Michael W. Nall, CEO, Pres & Director (Age 55)
- Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer & Member of Scientific Advisory Board (Age 71)
- Dr. Veena M. Singh, Sr. VP, Sr. Medical Director & Member of Scientific Advisory Board (Age 43)
- Dr. Soon Kap Hahn Ph.D., Founder
- Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations, Sec. & Principal Accounting Officer (Age 60)
Has Biocept been receiving favorable news coverage?
Press coverage about BIOC stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biocept earned a coverage optimism score of 0.15 on Accern's scale. They also gave news articles about the medical research company an impact score of 46.02 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Biocept?
Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biocept's stock price today?
One share of BIOC stock can currently be purchased for approximately $0.1825.
How big of a company is Biocept?
Biocept has a market capitalization of $12.41 million and generates $5.07 million in revenue each year. The medical research company earns $-21,610,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Biocept employs 95 workers across the globe.
How can I contact Biocept?
Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]
MarketBeat Community Rating for Biocept (BIOC)
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biocept (NASDAQ:BIOC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Biocept in the last 12 months. Their average twelve-month price target is $1.25, suggesting that the stock has a possible upside of 584.93%. The high price target for BIOC is $1.50 and the low price target for BIOC is $1.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $1.25 | $1.25 | $2.25 | $2.25 |
| Price Target Upside: | 584.93% upside | 420.83% upside | 251.56% upside | 251.56% upside |
Biocept (NASDAQ:BIOC) Consensus Price Target History
Biocept (NASDAQ:BIOC) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Biocept (NASDAQ:BIOC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Biocept (NASDAQ BIOC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 7.58%
Biocept (NASDAQ BIOC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/19/2016 | Claire Reiss | Major Shareholder | Buy | 227,272 | $1.10 | $249,999.20 | |  |
| 10/19/2016 | David F. Hale | Director | Buy | 90,909 | $1.10 | $99,999.90 | | |
| 10/19/2016 | Lyle J. Arnold | SVP | Buy | 45,000 | $1.10 | $49,500.00 | | |
| 10/19/2016 | Timothy Kennedy | CFO | Buy | 36,363 | $1.10 | $39,999.30 | | |
| 5/4/2016 | Bruce Gerhardt | Director | Buy | 25,000 | $1.00 | $25,000.00 | 58,985 | |
| 5/4/2016 | Claire Reiss | Major Shareholder | Buy | 614,273 | $1.00 | $614,273.00 | | |
| 2/13/2015 | David F Hale | Chairman | Buy | 40,000 | $1.25 | $50,000.00 | | |
| 2/13/2015 | Marsha Alpert Chandler | Director | Buy | 2,000 | $1.25 | $2,500.00 | | |
| 2/13/2015 | Michael W Nall | CEO | Buy | 12,000 | $1.25 | $15,000.00 | | |
(Data available from 1/1/2013 forward)
Biocept (NASDAQ BIOC) News Headlines
| Source: |
|
Biocept (NASDAQ:BIOC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Biocept (NASDAQ:BIOC) Income Statement, Balance Sheet and Cash Flow Statement
Biocept (NASDAQ BIOC) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
